Compare GMAB & SNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMAB | SNA |
|---|---|---|
| Founded | 1999 | 1920 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 18.1B |
| IPO Year | N/A | N/A |
| Metric | GMAB | SNA |
|---|---|---|
| Price | $31.78 | $347.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $40.40 | ★ $361.00 |
| AVG Volume (30 Days) | ★ 1.4M | 265.6K |
| Earning Date | 11-06-2025 | 10-16-2025 |
| Dividend Yield | N/A | ★ 2.81% |
| EPS Growth | ★ 132.41 | N/A |
| EPS | ★ 25.10 | 19.06 |
| Revenue | $3,845,670,022.00 | ★ $5,115,400,000.00 |
| Revenue This Year | $24.85 | N/A |
| Revenue Next Year | $16.67 | $3.42 |
| P/E Ratio | ★ $12.31 | $18.22 |
| Revenue Growth | ★ 29.57 | 0.24 |
| 52 Week Low | $17.24 | $289.81 |
| 52 Week High | $33.65 | $365.78 |
| Indicator | GMAB | SNA |
|---|---|---|
| Relative Strength Index (RSI) | 59.84 | 61.28 |
| Support Level | $31.32 | $335.88 |
| Resistance Level | $32.41 | $351.31 |
| Average True Range (ATR) | 0.64 | 6.25 |
| MACD | 0.11 | 1.35 |
| Stochastic Oscillator | 73.67 | 85.14 |
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Snap-on is a manufacturer of premium tools, equipment, and diagnostics for professional technicians, primarily involved in the repair of passenger cars, but has expanded into other industrial applications. The company's legacy business is selling hand tools through franchisee-operated mobile vans to technicians who purchase the tools at their own expense. The company also operates a commercial and industrial business, focusing on repair facilities that serve other industries. The third segment, repair systems and information, targets auto OEMs and large dealerships more directly, also offering substantial diagnostic solutions to aid in repairs. The company's finance arm provides financing to franchisees to support their operations, as well as underwrites end-customer purchases.